Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00221312
Status:
COMPLETED
Last Update Posted:
2008-05-08
First Post:
2005-09-16
Brief Title:
Fosamax Bone Loss Study Alendronate to Prevent Bone Loss
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Study Overview
Official Title:
Alendronate to Prevent Perimenopausal Transition Bone Loss
Status:
COMPLETED
Status Verified Date:
2005-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to determine if Fosamax alendronate a medication approved by the Food and Drug Administration FDA for the prevention and treatment of osteoporosis in postmenopausal women is effective in decreasing the rate of bone loss which often begins to increase in the three to five years preceding the menopause perimenopausal transition
During the three to five years prior to the menopause the rate of bone loss increases One way that physicians treat this is with oral contraceptive medication However the incidence of complications from oral contraceptives after the age of 40 increases Therefore a non-hormonal means of preventing bone loss should be useful Fosamax alendronate is in a class of compounds called bisphosphonates This study is being done to determine whether Fosamax can be used to prevent the increased rate of bone loss during the perimenopausal transition
During the three to five years prior to the menopause the rate of bone loss increases One way that physicians treat this is with oral contraceptive medication However the incidence of complications from oral contraceptives after the age of 40 increases Therefore a non-hormonal means of preventing bone loss should be useful Fosamax alendronate is in a class of compounds called bisphosphonates This study is being done to determine whether Fosamax can be used to prevent the increased rate of bone loss during the perimenopausal transition
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 39-62 | None | None | None |
| H675-20192-05 | None | None | None |